GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhongzhi Pharmaceutical Holdings Ltd (HKSE:03737) » Definitions » ROC %

Zhongzhi Pharmaceutical Holdings (HKSE:03737) ROC % : 1.99% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zhongzhi Pharmaceutical Holdings ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Zhongzhi Pharmaceutical Holdings's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was 1.99%.

As of today (2024-05-18), Zhongzhi Pharmaceutical Holdings's WACC % is 5.85%. Zhongzhi Pharmaceutical Holdings's ROC % is 13.22% (calculated using TTM income statement data). Zhongzhi Pharmaceutical Holdings generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Zhongzhi Pharmaceutical Holdings ROC % Historical Data

The historical data trend for Zhongzhi Pharmaceutical Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongzhi Pharmaceutical Holdings ROC % Chart

Zhongzhi Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.84 18.86 9.90 9.93 13.51

Zhongzhi Pharmaceutical Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 17.91 2.64 25.02 1.99

Zhongzhi Pharmaceutical Holdings ROC % Calculation

Zhongzhi Pharmaceutical Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=217.534 * ( 1 - 20.93% )/( (1219.487 + 1327.107)/ 2 )
=172.0041338/1273.297
=13.51 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2094.127 - 472.993 - ( 441.881 - max(0, 816.599 - 1218.246+441.881))
=1219.487

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1960.746 - 451.366 - ( 182.273 - max(0, 665.683 - 956.095+182.273))
=1327.107

Zhongzhi Pharmaceutical Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=37.922 * ( 1 - 29.63% )/( (1356.597 + 1327.107)/ 2 )
=26.6857114/1341.852
=1.99 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1952.218 - 323.374 - ( 272.247 - max(0, 644.763 - 1027.569+272.247))
=1356.597

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1960.746 - 451.366 - ( 182.273 - max(0, 665.683 - 956.095+182.273))
=1327.107

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhongzhi Pharmaceutical Holdings  (HKSE:03737) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Zhongzhi Pharmaceutical Holdings's WACC % is 5.85%. Zhongzhi Pharmaceutical Holdings's ROC % is 13.22% (calculated using TTM income statement data). Zhongzhi Pharmaceutical Holdings generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Zhongzhi Pharmaceutical Holdings ROC % Related Terms

Thank you for viewing the detailed overview of Zhongzhi Pharmaceutical Holdings's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongzhi Pharmaceutical Holdings (HKSE:03737) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Kangtai Road South, Torch Development Zone, Guangdong Province, Zhongshan, CHN
Zhongzhi Pharmaceutical Holdings Ltd is engaged in the business of manufacturing and selling pharmaceutical products. The group's operations can be divided into three segments, namely Pharmaceutical manufacturing, Operation of chain pharmacies, and Operation of online pharmacies in Zhongshan in the Guangdong province, the PRC. In the Pharmaceutical manufacturing segment, the company is engaged in the research and development, manufacturing and sale of Chinese patent medicines. In the Operation of chain pharmacies segment, the firm operates chain pharmacies in Zhongshan under the brand Zeus for the sale of pharmaceutical products. The Operation of online pharmacies segment sells medicines online. It derives a majority of its revenue from the PRC.

Zhongzhi Pharmaceutical Holdings (HKSE:03737) Headlines

No Headlines